Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease

Movement Disorders

Volumn 17, Issue 4, 2002, Pages 748-757

  Schiefer, Johannes ^a   Landwehrmeyer, G Bernhard ^b   Lüesse, Hans Gerd ^a   Sprünken, Arne ^a   Puls, Christiane ^a   Milkereit, Anna ^a   Milkereit, Eva ^a   Kosinski, Christoph M ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Excitotoxicity; Glutamate antagonism; Neurodegenerative disease; Neuroprotection; Polyglutamine disease

Indexed keywords

ANTIBODY; GLUTAMIC ACID; RILUZOLE; AMINO ACID RECEPTOR BLOCKING AGENT; HD PROTEIN, HUMAN; HDH PROTEIN, MOUSE; NERVE PROTEIN; NEUROPROTECTIVE AGENT; NUCLEAR PROTEIN;

ANIMAL MODEL; ARTICLE; CELL NUCLEUS INCLUSION BODY; EXON; GENE EXPRESSION; HUNTINGTON CHOREA; IMMUNOHISTOLOGY; LOCOMOTION; MOTOR COORDINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAINING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TRANSGENIC MOUSE; UBIQUITINATION; WEIGHT REDUCTION; ANIMAL; BRAIN CORTEX; CELL NUCLEUS; CORPUS STRIATUM; ENZYME IMMUNOASSAY; GENETICS; HUMAN; MOTOR PERFORMANCE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SURVIVAL; TRINUCLEOTIDE REPEAT;

ANIMALS; CELL NUCLEUS; CEREBRAL CORTEX; CORPUS STRIATUM; EXCITATORY AMINO ACID ANTAGONISTS; EXONS; GLUTAMIC ACID; HUMANS; HUNTINGTON DISEASE; IMMUNOENZYME TECHNIQUES; MICE; MICE, TRANSGENIC; MOTOR SKILLS; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; RILUZOLE; SURVIVAL ANALYSIS; TRINUCLEOTIDE REPEATS;

EID: 0036652765     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10229     Document Type: Article

References (41)

1. Huntington G. On chorea. Med Surg Rep 1872;26:317-321.
2. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
3. Wellington CL, Brinkman RR, Kusky J, Hayden MR. Toward understanding the molecular pathology of Huntington's disease. Brain Pathol 1997;7:979-1002.
4. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996;87:493-506.
5. Carter RJ, Hunt MJ, Morton AJ. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov Disord 2000;15:925-937.
6. Carter RJ, Lione LA, Humby T, et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 1999;19:3248-3257.
7. Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, Dunnett SB. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci 1999;19:10428-10437.
8. Davies S, Turmaine M, Cozens B, et al. Formation of neuronal intranuclear inclusions (NII) underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997;90:537-548.
9. DiFiglia M, Sapp E, Chase K, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277:1990-1993.
10. Davies S, Beardsall K, Turmaine M, DiFiglia M, Aronin N, Bates G. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? Lancet 1998;351:131-133.
11. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 1991;11:1649-1659.
12. Cha JH, Kosinski CM, Kerner JA, et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci U S A 1998;95:6480-6485.
13. Cha JH, Frey AS, Alsdorf SA, et al. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos Trans R Soc Lond B 1999;354:1-9.
14. Behrens P, Franz P, Bates GP, Landwehrmeyer G. Progressively increasing extracellular levels of glutamate evoked by tPDC in the caudate putamen of a transgenic mouse model of Huntington's disease: an in vivo microdialysis study. Soc Neurosci Abstr 2000;382:385.
15. Icton C, Zeron M, Wellington C, Leavitt B, Hayden M, Raymond L. Probing the interaction between huntingtin and NMDA receptors. Soc Neurosci Abstr 2000;382:317.
16. Zeron MM, Chen N, Moshaver A, et al. Mutant huntingtin enhances excitotoxic cell death. Mol Cell Neurosci 2001;17:41-53.
17. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997;41:160-165.
18. Taylor-Robinson SD, Weeks RA, Bryant DJ, et al. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord 1996;11: 167-173.
19. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996;47:S233-S241.
20. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157.
21. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
22. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/riluzole Study Group II. Lancet 1996;347:1425-1431.
23. Hurlbert M, Zhou W, Wasmeier C, Kaddis F, Hutton J, Freed C. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 1999;48:649-651.
24. Kosinski C, Cha J-H, Young A, et al. Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice. Neuroreport 1999;10:3891-3896.
25. Lunkes A, Trottier Y, Fagart J, et al. Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease. Philos Trans R Soc Lond B Biol Sci 1999;354:1013-1019.
26. Kosinski C, Bradley S, Conn P, et al. Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein expression in the rat basal ganglia. J Comp Neurol 1999;415:266-284.
27. Kosinski C, Cha J, Young A, et al. Huntingtin immunoreactivity in the rat neostriatum: differential accumulation in projection and interneurons. Exp Neurol 1997;144:239-247.
28. Lüesse H, Schiefer J, Sprünken A, Puls C, Block F, Kosinski CM. Evaluation of R6/2 transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. Behav Brain Res 2001;126:185-195.
29. Reddy PH, Williams M, Charles V, et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 1998;20:198-202.
30. Rosas HD, Koroshetz WJ, Jenkins BG, et al. Riluzol therapy in Huntington's disease (HD). Mov Disord 1999;14:326-330.
31. Saudou F, Finkbeiner S, Devys D, Greenberg M. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998;95:55-66.
32. Kim M, Lee HS, LaForet G, et al. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci 1999;19:964-973.
33. Klement IA, Skinner PJ, Kaytor MD, et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998;95:41-53.
34. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797-801.
35. Ona VO, Li M, Vonsattel JP, et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999;399:263-267.
36. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000;20:4389-4397.
37. Andreassen OA, Ferrante RJ, Huang HM, et al. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann Neurol 2001;50:112-117.
38. Malcon C, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine administration against NMDA and malonate toxicity. Brain Res 2000;860:195-198.
39. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000;101:57-66.
40. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357-366.
41. Kosinski C, Standaert D, Counihan T, et al. Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: striatum and globus pallidus. J Comp Neurol 1998;390:63-74.M